10x Genomics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
May 04, 2022 at 09:06 pm
Share
10x Genomics, Inc. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was USD 114.5 million compared to USD 105.82 million a year ago. Net loss was USD 42.41 million compared to USD 11.55 million a year ago. Basic loss per share from continuing operations was USD 0.38 compared to USD 0.11 a year ago.
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for analyzing biological systems. Its Chromium platform includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, and others.